New Paradigm Biosciences

Executive Summary

New Paradigm Biosciences (NPB) is a private biotechnology company developing novel immunotherapies for cancer by targeting uniquely human immune system components. Founded in 2019 and headquartered in San Francisco, NPB leverages a proprietary humanized mouse platform to create more predictive in vivo models for drug discovery and validation. This approach aims to overcome the limitations of conventional animal models, potentially enabling the development of therapeutics that are more effective in humans. While still in early stages, NPB's focus on human-specific immune targets and advanced modeling may position it to address significant unmet needs in oncology.

Upcoming Catalysts (preview)

• Q4 2026Lead IND Filing for First Immunotherapy Candidate30% success
• Q2 2026Strategic Partnership or Licensing Deal for Humanized Mouse Platform50% success
• Q3 2026Publication of Preclinical Data from Lead Program60% success